Trastuzumab Deruxtecan,Capecitabine,Eribulin,Gemcitabine,Paclitaxel,Nab-paclitaxel
Daiichi Sankyo,AstraZeneca
['mbc', 'db-04', 't-dxd']
db-04 sub-analysis: t-dxd outperformed chemo in her2-low mbc irrespective of intrinsic subtype, esr1 status, pik3ca status and cdk4/6i resistance markers. highest activity of t-dxd in her2-enriched (orr &gt;60%!) #asco23 
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale | former @IEOufficiale. Interested in breast oncology, HER2, ADCs & good music.